Regulatory T cells modulate granulomatous inflammation in an HLA-DP2 transgenic murine model of beryllium-induced disease

Significance Genetic linkage to major histocompatibility complex class II proteins has been observed in many immunological disorders; yet, little is known about the underlying mechanisms of these associations. For chronic beryllium disease (CBD), the linkage to HLA-DPB1 alleles encoding a glutamic acid at position 69 of the β-chain is well established. We tested whether the presence of HLA-DP2 is sufficient for the development of a disease-specific model of CBD. HLA-DP2 transgenic mice developed a beryllium-specific adaptive immune response composed of CD4+ T cells that secrete Th1-type cytokines and are HLA-DP2-restricted, thus replicating the major features of the human disease. In addition, regulatory T cells modulate granuloma formation in the lungs of beryllium oxide-exposed HLA-DP2 transgenic mice. Susceptibility to chronic beryllium disease (CBD) is linked to certain HLA-DP molecules, including HLA-DP2. To elucidate the molecular basis of this association, we exposed mice transgenic (Tg) for HLA-DP2 to beryllium oxide (BeO) via oropharyngeal aspiration. As opposed to WT mice, BeO-exposed HLA-DP2 Tg mice developed mononuclear infiltrates in a peribronchovascular distribution that were composed of CD4+ T cells and included regulatory T (Treg) cells. Beryllium-responsive, HLA-DP2–restricted CD4+ T cells expressing IFN-γ and IL-2 were present in BeO-exposed HLA-DP2 Tg mice and not in WT mice. Using Be-loaded HLA-DP2–peptide tetramers, we identified Be-specific CD4+ T cells in the mouse lung that recognize identical ligands as CD4+ T cells derived from the human lung. Importantly, a subset of HLA-DP2 tetramer-binding CD4+ T cells expressed forkhead box P3, consistent with the expansion of antigen-specific Treg cells. Depletion of Treg cells in BeO-exposed HLA-DP2 Tg mice exacerbated lung inflammation and enhanced granuloma formation. These findings document, for the first time to our knowledge, the development of a Be-specific adaptive immune response in mice expressing HLA-DP2 and the ability of Treg cells to modulate the beryllium-induced granulomatous immune response.

[1]  D. Tran,et al.  Peripheral and Thymic Foxp3+ Regulatory T Cells in Search of Origin, Distinction, and Function , 2013, Front. Immunol..

[2]  Radleigh G. Santos,et al.  Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease , 2013, The Journal of experimental medicine.

[3]  J. Bluestone,et al.  Peripherally Induced Tregs – Role in Immune Homeostasis and Autoimmunity , 2013, Front. Immunol..

[4]  Daniel J. Kuster,et al.  Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo , 2012, The Journal of experimental medicine.

[5]  J. Weiss,et al.  Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells , 2012, The Journal of experimental medicine.

[6]  L. Newman,et al.  Beryllium-specific CD4+ T cells in blood as a biomarker of disease progression. , 2011, The Journal of allergy and clinical immunology.

[7]  K. Takatsu,et al.  Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis , 2010, The Journal of experimental medicine.

[8]  B. Palmer,et al.  Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects. , 2010, American journal of respiratory and critical care medicine.

[9]  Douglas G. Mack,et al.  Crystal structure of HLA-DP2 and implications for chronic beryllium disease , 2010, Proceedings of the National Academy of Sciences.

[10]  E. Rubin,et al.  Genetic determinants of sensitivity to beryllium in mice , 2009, Journal of immunotoxicology.

[11]  T. A. Butler,et al.  Certification of beryllium mass fraction in SRM 1877 Beryllium Oxide Powder using high-performance inductively coupled plasma optical emission spectrometry with exact matching. , 2009, Analytical Chemistry.

[12]  J. Bill,et al.  Beryllium Presentation to CD4+ T Cells Is Dependent on a Single Amino Acid Residue of the MHC Class II β-Chain1 , 2005, The Journal of Immunology.

[13]  A. Fontenot,et al.  Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. , 2005, Trends in immunology.

[14]  B. Palmer,et al.  Frequency of beryllium-specific, TH1-type cytokine-expressing CD4+ T cells in patients with beryllium-induced disease. , 2005, The Journal of allergy and clinical immunology.

[15]  Mark D. Hoover,et al.  Surface area of respirable beryllium metal, oxide, and copper alloy aerosols and implications for assessment of exposure risk of chronic beryllium disease. , 2003, AIHA journal : a journal for the science of occupational and environmental health and safety.

[16]  M. Andrew,et al.  HLA-DPB1 and chronic beryllium disease: a HuGE review. , 2003, American journal of epidemiology.

[17]  Mark D. Hoover,et al.  Efficacy of a Technique for Exposing the Mouse Lung to Particles Aspirated from the Pharynx , 2003, Journal of toxicology and environmental health. Part A.

[18]  R. Lechler,et al.  HLA-DP Allele-Specific T Cell Responses to Beryllium Account for DP-Associated Susceptibility to Chronic Beryllium Disease1 , 2001, The Journal of Immunology.

[19]  L. Newman,et al.  Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Sakaguchi Regulatory T cells , 2006, Springer Seminars in Immunopathology.

[21]  K. Urdahl,et al.  Foxp3(+) regulatory T cells in tuberculosis. , 2013, Advances in experimental medicine and biology.

[22]  David Bouchez,et al.  Manipulating the Mouse Embryo , 2007 .

[23]  E. Shevach Regulatory T cells in autoimmmunity*. , 2000, Annual review of immunology.

[24]  B. Hogan,et al.  Manipulating the mouse embryo: A laboratory manual , 1986 .